Here's Novo Nordisk's First Oral Obesity Drug In Europe With Proven Heart Health Impact

On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.

SOUL was a phase 3b trial carried out to evaluate the effect of Rybelsus on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).

Rybelsus is now the first and only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA), mimicking a natural hormone in the body that helps regulate blood sugar, appetite, and digestion, available in the EU for type 2 diabetes with a proven cardiovascular benefit.

Also Read: Wegovy And Zepbound Cost-Effective, But They Could Break Drug ...